Effect of Probiotic and Smectite Gel on NAFLD

Non-Alcoholic Fatty Liver Disease Clinical Trial

Official title:

Effect of Alive Probiotics Supplementation With Absorbent Smectite Gel in NAFLD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03614039
• Other study ID #: ENDO-3
• Status: Completed
• Phase: N/A
• Start date: September 15, 2015
• Est. completion date: April 20, 2016

Study information

• Verified date: August 2018
• Source: Bogomolets National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Smectite is a natural silicate clay belonging to the dioctahedral smectite class and has the ability directly to absorb bacterial toxins, bacteria, viruses and bile salts. Diosmectite also has a protective effect against intestinal inflammation hence suppressing production of cytokines such as IL-8 and TNFα. Investigators suggested that all these pharmacological properties may be beneficial for the treatment of NAFLD. Based on preclinical data, in rats with MSG induced obesity supplementation of alive probiotics with smectite gel (Symbiter-Forte) due to his absorbent activity lead to significant reduction of chronic systemic inflammatory markers, lower total NAS (NAFLD activity score) score, with more pronounced reduction of lobular inflammation as compared to administration of probiotic alone. In respect to preclinical data, in this double-blind single center randomized clinical trial (RCT) the efficacy of alive probiotics supplementation with smectite gel (Symbiter-Forte) vs. placebo in type-2 diabetes patient with NAFLD detected on ultrasonography will be studied

Description:

In this single-center double-blind, placebo controlled, parallel group study, 50 T2D patients from the Kyiv City Clinical Endocrinology Center - Ukraine, were selected. They were randomly assigned to receive "Symbiter Forte" or placebo for 8 weeks, administered as a sachet formulation in double-blind treatment. Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.

The "Symbiter Forte" was supplied by Scientific and Production Company "O.D. Prolisok". It contains combination of smectite gel (250 mg), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patients received 1 sachet (10 grams) of probiotic-smectite and placebo per day. All sachets were identical with similar organoleptic characteristics (e.g., taste and appearance).

The pre-randomization period was designed to minimize the effects of dietary changes on metabolic markers. For this purpose, 2 weeks before the study started, after the informed consent was signed, patients were instructed in one-on-one sessions with a dietitian to follow a therapeutic lifestyle-change diet as classified by the NCEP. In addition, participants were instructed to continue with stable anti-hyperglycemic treatment and received standardized mild physical training for 1 hour per day.

Patients who underwent the study were instructed to take the trial medication as prescribed. Throughout the study, weekly phone follow-up visits were provided for assessment of compliance, adherence to the protocol, as well as the recording of adverse events. The effectiveness of therapy was compared and evaluated separately in the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 20, 2016
• Est. primary completion date: March 15, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• adult participants (ages 18-75, BMI =25 kg/m2) diagnosed with NAFLD according to the recommendations of the American Gastroenterology Association (AGA) and American Association for the Study of Liver Disease (AASLD);

• the diagnosis of fatty liver was based on the results of abdominal ultrasonography. Of 4 known criteria (hepato-renal echo contrast, liver brightness, deep attenuation, and vascular blurring), the participants were required to have hepato-renal contrast and liver brightness to be given a diagnosis of NAFLD.

• type 2 diabetes treated with diet and exercise alone or metformin, SUs and insulin at stable dose at least 4 weeks prior to the commencement of the study;

• AST and ALT =3x upper limit of normal.

Exclusion Criteria:

• alcohol abuse (>20 g/day (2 standard drinks) in women or > 30 g/d (3 drinks) in men over a two-year period);

• chronic viral hepatitis (associated with HBV, HCV, HDV infection);

• drug-induced liver disease, Wilson's disease, hereditary deficiency of antitrypsin-1 and idiopathic hemochromatosis;

• history of decompensated liver disease including ascites, encephalopathy or variceal bleeding;

• regular use of a probiotic or prebiotic supplement within 3 months prior to enrollment;

• antibiotic use within 3 months prior to enrollment;

• uncontrolled cardiovascular or respiratory disease, active malignancy, or chronic infections;

• use of agents such as vitamin E, omega-3 fatty acids or medications with evidence for effects on NAFLD (pioglitazone, GLP-1 analogues, dipeptidyl peptidase IV inhibitors, ursodeoxycholic acid);

• presence of active infection, pregnancy or lactation.

Related Conditions & MeSH terms

• Digestive System Diseases
• Fatty Liver
• Gastrointestinal Diseases
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease
• Type2 Diabetes

Intervention

Dietary Supplement:
• "Symbiter Forte"
"Symbiter Forte" which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)
• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Nazarii Kobyliak

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	fatty liver index (FLI)	FLI = [e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745)] × 100	8 weeks compared to baseline
Primary	liver stiffness (LS)	liver stiffness (LS) was measured by Shear Wave Elastography (SWE) and expressed in kPa	8 weeks compared to baseline
Secondary	ALT	ALT in IU/L	8 weeks compared to baseline
Secondary	AST	AST in IU/L	8 weeks compared to baseline
Secondary	?-GT	?-GT in IU/L	8 weeks compared to baseline
Secondary	Total Cholesterol (TC)	TC in mmol/l	8 weeks compared to baseline
Secondary	Tryglicerides (TG)	TG in mmol/l	8 weeks compared to baseline
Secondary	LDL-Cholesterol (LDL-C)	LDL-C in mmol/l	8 weeks compared to baseline
Secondary	VLDL-Cholesterol (VLDL-C)	VLDL-C in mmol/l	8 weeks compared to baseline
Secondary	HDL-Cholesterol (HDL-C)	HDL-C in mmol/l	8 weeks compared to baseline
Secondary	cytokines levels	TNF-a, IL-1ß, IL-6, IL-8, INF-? in pg/ml	8 weeks compared to baseline